Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
6 min read
Reslizumab Biologics Sequence Review Report 2026: IL-5 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Reslizumab, an antibody targeting IL-5.
6 min read
Mepolizumab Biologics Sequence Review Report 2026: IL-5 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Mepolizumab, an antibody targeting IL-5.
6 min read
Tezepelumab Biologics Sequence Review Report 2026: TSLP Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tezepelumab, an antibody targeting TSLP.
6 min read
Ligelizumab Biologics Sequence Review Report 2026: IgE Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ligelizumab, an antibody targeting IgE.
6 min read
Omalizumab Biologics Sequence Review Report 2026: IgE Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Omalizumab, an antibody targeting IgE.
6 min read
Tralokinumab Biologics Sequence Review Report 2026: IL-13 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tralokinumab, an antibody targeting IL-13.
6 min read
Lebrikizumab Biologics Sequence Review Report 2026: IL-13 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lebrikizumab, an antibody targeting IL-13.
6 min read
Dupilumab Biologics Sequence Review Report 2026: IL-4RA Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Dupilumab, an antibody targeting IL-4RA.
6 min read
Nemolizumab Biologics Sequence Review Report 2026: IL-31RA Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Nemolizumab, an antibody targeting IL-31RA.
6 min read
Spesolimab Biologics Sequence Review Report 2026: IL-36R Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Spesolimab, an antibody targeting IL-36R.
6 min read
Clesrovimab Biologics Sequence Review Report 2026: RSV F protein Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Clesrovimab, an antibody targeting RSV F protein.
6 min read
Bimekizumab Biologics Sequence Review Report 2026: IL-17A/IL-17F Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Bimekizumab, an antibody targeting IL-17A/IL-17F.